1255099-06-9Relevant academic research and scientific papers
Application of RhoGDI inhibitor to preparation of drugs for treating nasopharynx cancer
-
Paragraph 0035; 0040; 0041, (2018/07/06)
The invention discloses application of a RhoGDI inhibitor to the preparation of drugs for treating nasopharynx cancer. The invention further discloses application of a RhoGDI inhibitor to the preparation of nasopharynx cancer radiotherapy sensitizer. The invention further discloses a drug for treating nasopharynx cancer, which adopts a preparation prepared from the RhoGDI inhibitor taken as an active component and pharmaceutically acceptable auxiliary materials. The RhoGDI inhibitor achieves the effects of tumor growth resistance, tumor metastasis resistance and radiotherapy sensitivity through specific inhibition of RhoGDI expression and activation of a JNK-1 pathway at the downstream (namely the activation of the expression of downstream p-JNK-1, c-Jun, inhibition the expression of p-AKT, enhancement the conversion of pro-caspase-3 to cleaved-caspase-3), and has a good clinical application prospect.
